Ongoing clinical trials are investigating neratinib both as a monotherapy and in combination regimens for HER2‐positive breast cancer with brain metastases, as well as for other malignancies such as HER2‐mutant non‐small cell lung cancer [10, 11, 12, 13]. This evidence concerns the gene ERBB2 and breast cancer.